Phase 2 KRAS G12C Clinical Trials
10 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–10 of 10 trials
Recruiting
Phase 1Phase 2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Colorectal, CancerColorectal CarcinomaNon-small Cell Lung Cancer+29 more
Institut de Recherches Internationales Servier554 enrolled27 locationsNCT05786924
Recruiting
Phase 1Phase 2
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung CancerAdvanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals40 enrolled1 locationNCT07468071
Recruiting
Phase 2
Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
Colorectal, CancerKRAS G12C Mutant Advanced Solid TumorsFulzerasib+1 more
Zhejiang University40 enrolled1 locationNCT07581912
Recruiting
Phase 2
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
PI3K Gene MutationKRAS G12DVascular Anomalies+15 more
Murdoch Childrens Research Institute50 enrolled2 locationsNCT05983159
Recruiting
Phase 2
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Non-small Cell Lung CancerNSCLCKRAS G12C
Ryan Gentzler, MD30 enrolled3 locationsNCT06248606
Recruiting
Phase 2
Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
Neoadjuvant TherapyKRAS G12C MutationResectable NSCLC+1 more
Jianxing He30 enrolled3 locationsNCT07492342
Recruiting
Phase 1Phase 2
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Colorectal, CancerPancreatic CancerMetastatic Solid Tumor+5 more
Frontier Medicines Corporation403 enrolled26 locationsNCT06244771
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Non-small Cell Lung Cancer (NSCLC)KRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more
Revolution Medicines, Inc.616 enrolled89 locationsNCT06162221
Recruiting
Phase 1Phase 2
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
Metastatic Colorectal CancerKRAS G12C Mutations
M.D. Anderson Cancer Center31 enrolled2 locationsNCT06412198
Active
Phase 2
SHERLOCK: Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation
advanced non-squamous non-small cell lung cancer
with KRAS G12C mutation
The University of Sydney52 enrolled13 locationsACTRN12622000973718